Clinical Trial Detail

NCT ID NCT01356290
Title Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Medical University of Vienna
Indications

medulloblastoma

Therapies

Thalidomide

Fenofibrate

Etoposide

Bevacizumab

Celecoxib

Cyclophosphamide + Cytarabine

Age Groups: adult child

No variant requirements are available.